News coverage about Second Sight Medical Products (NASDAQ:EYES) has trended somewhat positive recently, according to Accern Sentiment Analysis. Accern identifies negative and positive press coverage by monitoring more than 20 million news and blog sources in real time. Accern ranks coverage of public companies on a scale of -1 to 1, with scores closest to one being the most favorable. Second Sight Medical Products earned a coverage optimism score of 0.13 on Accern’s scale. Accern also gave media coverage about the medical device company an impact score of 44.2552182718572 out of 100, meaning that recent press coverage is somewhat unlikely to have an effect on the company’s share price in the near term.
These are some of the headlines that may have impacted Accern Sentiment’s scoring:
- Comparing Second Sight Medical Products (EYES) & Its Rivals (americanbankingnews.com)
- Second Sight Medical Products (EYES) & Its Competitors Head-To-Head Review (americanbankingnews.com)
- Second Sight Medical Products (EYES) vs. Its Rivals Head-To-Head Comparison (americanbankingnews.com)
- Critical Review: Second Sight Medical Products (EYES) versus The Competition (americanbankingnews.com)
- Zacks: Second Sight Medical Products, Inc. (EYES) Given $5.00 Average Target Price by Brokerages (americanbankingnews.com)
Shares of Second Sight Medical Products (NASDAQ EYES) opened at $1.89 on Monday. The stock has a market capitalization of $105.69, a price-to-earnings ratio of -2.82 and a beta of 3.67. Second Sight Medical Products has a 1-year low of $0.90 and a 1-year high of $2.83.
Several equities analysts have recently commented on EYES shares. Zacks Investment Research lowered Second Sight Medical Products from a “hold” rating to a “sell” rating in a research note on Thursday, November 9th. HC Wainwright set a $5.00 price target on Second Sight Medical Products and gave the company a “buy” rating in a research note on Tuesday, October 17th.
COPYRIGHT VIOLATION WARNING: “Second Sight Medical Products (EYES) Earning Somewhat Positive Media Coverage, Analysis Finds” was first posted by Community Financial News and is the property of of Community Financial News. If you are viewing this story on another website, it was copied illegally and republished in violation of United States & international copyright & trademark law. The original version of this story can be accessed at https://www.com-unik.info/2017/12/25/second-sight-medical-products-eyes-earning-somewhat-positive-media-coverage-analysis-finds.html.
About Second Sight Medical Products
Second Sight Medical Products, Inc is engaged in developing, manufacturing and marketing prosthetic devices that restore vision to blind individuals. The Company’s product, the Argus II System, treats outer retinal degenerations, such as retinitis pigmentosa (RP). The Argus II System provides an artificial form of vision that differs from the vision of people with normal sight.
Receive News & Ratings for Second Sight Medical Products Daily - Enter your email address below to receive a concise daily summary of the latest news and analysts' ratings for Second Sight Medical Products and related companies with MarketBeat.com's FREE daily email newsletter.